Pliant Therapeutics (PLRX) Heading Into a Positive Catalyst Mid-Year - RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $35.00 price target on Pliant Therapeutics (NASDAQ: PLRX) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
